rHEALTH Targets $323 Billion Diagnostics Market with NASA-Backed Testing Tech

rHEALTH is positioning itself to disrupt the global blood diagnostics market with a portable, lab-quality testing device designed for use in point-of-care settings and eventually private homes. The system aims to address a critical gap in global healthcare, as the World Health Organization estimates that 4.5 billion people lack timely access to diagnostic testing. Originally developed to monitor astronaut health on the International Space Station, the technology has been tested in extreme conditions and published in peer-reviewed journals. The rHEALTH ONE platform is protected by 17 U.S. patents covering its device architecture and diagnostic algorithms, allowing it to run more than 100 different tests from a single self-collected blood sample. The company has secured over $20 million in non-dilutive funding and established strategic partnerships with high-profile institutions, including the Mayo Clinic, Boston Children’s Hospital, and AstraZeneca. rHEALTH is currently working toward FDA registration, which is expected within the next 12 months. By targeting a $323 billion global diagnostics and patient monitoring market, rHEALTH intends to shift healthcare toward a decentralized model. The company's business strategy involves multiple revenue streams, including direct device sales, recurring sales of test cartridges, and software subscriptions.